SS
TPTX

Steve Schonfeld’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Steve Schonfeld’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,813
Closed -$830K – 2271
2020
Q4 		$830K Sell
6,813
-13,002
-66% -$1.42M 0.01% 871
2020
Q3 		$1.73M Buy
19,815
+10,137
+105% +$706K 0.03% 545
2020
Q2 		$625K Buy
+9,678
New +$558K 0.02% 732
2020
Q1 		– Sell
-9,700
Closed -$604K – 1646
2019
Q4 		$604K Sell
9,700
-81,900
-89% -$3.9M 0.01% 674
2019
Q3 		$3.44M Buy
+91,600
New +$3.99M 0.1% 214

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Steve Schonfeld's TPTX Position: Q1 2021 in Review

Steve Schonfeld sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2021, closing a stake of 6,813 shares — an estimated $830K sold.

Steve Schonfeld first reported a position in TPTX in Q3 2019 and held it in 5 quarters. The position peaked at $3.44M in Q3 2019. 202 funds tracked by Wall St. Rank hold TPTX as of Q1 2021.

  • Steve Schonfeld reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Steve Schonfeld sold 6,813 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $830K.
  • Steve Schonfeld first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Steve Schonfeld's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.44M in Q3 2019.
  • 202 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.